RxDoctor Payments Data

Amy Griffin, MD

Family Medicine · Alexandria, LANPI 1972594919

Payments from drug & device makers

$2,011in general payments, 2019–2025

Across 192 payments — averaging $10.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$538
  • Pfizer$308
  • Novo Nordisk$222
  • GSK$202
  • AstraZeneca$125
  • Takeda Pharmaceuticals U.S.A., Inc.$106
  • plus $511 from 11 others

What the payments were for

  • Food & beverage$1,99899%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,011 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$352,574
Medicare patients
1,294
Services billed
14,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide238$293,807
JardianceEmpagliflozin125$138,257
TrulicityDulaglutide55$98,684
MounjaroTirzepatide52$68,604
JanuviaSitagliptin Phosphate45$65,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$62,682
EliquisApixaban66$58,973
MyrbetriqMirabegron46$35,734
LinzessLinaclotide37$34,613
Nurtec OdtRimegepant Sulfate24$26,790
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$24,263
TrintellixVortioxetine Hydrobromide15$14,984
XareltoRivaroxaban11$14,793
FarxigaDapagliflozin Propanediol14$13,696
GemtesaVibegron16$11,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$222$293,807238 claims
Lilly USA, LLCTrulicity, Mounjaro$38$167,288107 claims
Boehringer IngelheimJardiance$75$138,257125 claims
PfizerEliquis, Nurtec Odt, Premarin$308$95,220123 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$202$73,307100 claims
MerckJanuvia$102$65,41745 claims
AbbVieLinzess, Synthroid$538$41,612187 claims
Astellas Pharma US IncMyrbetriq$37$35,73446 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$106$14,98415 claims
Johnson & JohnsonXarelto$12$14,79311 claims
AstraZenecaFarxiga$125$13,69614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →